Facilities

New facilities with state-of-the-art equipment

In January 2023, Clean Cells opened its new cGMP-compliant facility, a cutting-edge 5 300 m2 platform which considerably extends our biopharma capacities.

Our new facility has quadrupled our testing capacity for our portfolio of GMP-compliant biopharmaceutical products.

As such, biosafety testing grow substantially and multiply capacity for microbiology testing, adventitious virus testing and viral safety testing in accordance with worldwide regulatory guidelines.

Product characterization, including impurity, identity testing, potency and cytotoxicity testing also benefit from the extension with two major innovations in biopharma services:

  • Consolidation of karyotyping and identity testing: intended for veterinary products and Cell & Gene therapy products as CAR-T therapeutics (includes FISH analysis)
  • Next-Generation Sequencing : newest addition to our biopharma services portfolio to support identity and safety of biologics
Quality Control Labs - Clean Cells

Clean Cells new facility also consist of several cGMP biomanufacturing suites for cell and virus banks.

Operating 9 state-of-the-art GMP cell and virus bank manufacturing suites in a brand-new facility, Clean Cells accommodates various suspension and adherence-based technologies. These BSL2 suites undergo continuous environmental monitoring and equipment surveillance to meet regulatory expectations.

Clean Cells offers cell and virus bank manufacturing services in both non-GMP and GMP environments, supported by an advanced Quality Management System (QMS) to maintain traceability and proper documentation.

Manufacturing Labs - Clean Cells

Together with our biologics testing and characterization capabilities, this result in an integrated offer, from research bank to fully characterized GMP cell and virus banks, readily usable for further bioprocesses and biopharma applications.

Clean Cells’ new site opens a new chapter in the company’s rich history.

Request a visit